PT - JOURNAL ARTICLE AU - López-Velazco, Joanna I. AU - Manzano, Sara AU - Otaño, María AU - Elorriaga, Kepa AU - Bultó, Núria AU - Herrero, Julio AU - Lahuerta, Ainhara AU - Segur, Virginia AU - Álvarez-López, Isabel AU - Caffarel, Maria M. AU - Urruticoechea, Ander TI - A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer AID - 10.1101/2023.02.02.23285373 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.02.23285373 4099 - http://medrxiv.org/content/early/2023/08/11/2023.02.02.23285373.short 4100 - http://medrxiv.org/content/early/2023/08/11/2023.02.02.23285373.full AB - Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive/HER2-negative breast cancer (ER+/HER2-BC) allows real-time evaluation of drug efficacy and biological changes upon estrogenic deprivation. Clinical and pathological evaluation after NET may be used to obtain prognostic and predictive information of tumour response. Scales developed to evaluate response after neoadjuvant chemotherapy are not useful and there are not many validated biomarkers to assess response to NET. In this prospective study, we analysed radiological and pathological tumour response of 104 postmenopausal ER+/HER2-BC patients, treated with NET for a mean of 7 months. Our results show that radiological evaluation underestimates pathological tumour size, although it can be used to assess tumour response. In addition, we propose that the tumour cellularity size (TCS), calculated as the product of the residual tumour cellularity in the surgical specimen and the tumour pathological size, could become a new tool to standardize response assessment to NET. It is simple, reproducible and correlates with the existing biomarkers. Our findings shed light on the dynamics of NET response, challenge the paradigm of the ability of NET to decrease surgical volume and point to the utility of the TCS to quantify the scattered tumour response usually produced by endocrine therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Spanish Ministry of Science and Innovation ISCIII (P20/01253, CP18/00076 and FI19/00193) and European Regional Development (FEDER) funds, Basque Department of Health (2020111040), Fundacion SEOM (SEOM Avon Fellowship 2020) and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patients charity Katxalin and from Roche Farma S.A. JILV is funded by an AECC PhD Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Spain Health Authority and Diputacion de Gipuzkoa gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data for this study are available upon reasonable request.